Gilead Sciences, Inc. (GILD) Institutional Ownership & Insider Trading

2,269 institutions reported holding Gilead Sciences, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 82 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

GILDGilead Sciences, Inc.Follow GILD — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 193.5B
P/E TTM: —
Dividend yield: 2.1%
52-week: —
Next earnings: 29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

2,269 institutions held 89.9% of the shares. Across filers that reported both quarters, shares held changed +0.1%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	2,269	1114	+0.1%	758	91	691	133
Mar 26	2,290	1058	-1.8%	697	174	762	75
Dec 25	2,155	1086	-1.2%	699	158	588	80
Sep 25	1,973	1073	+1.4%	634	113	574	87
Jun 25	1,981	1071	+1.0%	664	128	609	116
Mar 25	1,959	1038	-0.3%	547	199	697	79
Dec 24	1,823	1060	+0.8%	507	124	603	64
Sep 24	1,671	1024	-1.7%	502	112	572	85

Gilead Sciences, Inc. — questions

Who owns Gilead Sciences, Inc. stock?: 2,269 institutions reported Gilead Sciences, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (9.8%), VANGUARD CAPITAL MANAGEMENT LLC (6.5%), FMR LLC (5.4%).
Are Gilead Sciences, Inc. insiders buying or selling?: 82 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Gilead Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.